Claudio Gasperini
Claudio Gasperini is an expert in Neurology at Azienda Ospedaliera San Camillo-Forlanini (Italy). As of October 2026, ScienceLeadR ranks Claudio Gasperini in the top 1% of experts worldwide for Multiple Sclerosis and Autoimmune Diseases. Claudio Gasperini has authored 443 publications, the most recent in 2026, and is an investigator in 11 clinical trials, 4 of them ongoing. SLR score: 1,097 (community average: 125). How the SLR is computed.
LeadR Profile
Neurology
Subspecialties: Immunology - Neurosurgery - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Claudio Gasperini MD PHD is currently Head of Neurology in the Department of Neurosciences of the S Camillo-Forlanini Hospital and Teacher of Neurology at the University La Sapienza of Rome. He graduated in Medicine and completed his specialist training in neurology at the University of La Sapienza of Rome. He then spent one year as Fellow in the Institute of Neurology in London directed by Professor WI McDonald. He obtained his PhD in the Department of Neuroscience at University of La Sapienza in Rome. Particular field of interest is Multiple Sclerosis. He is member of the Steering Committee of MAGNIMS (Magnetic Resonance Imaging in MS) that is a European network of academics sharing a common interest in the study of multiple sclerosis using MRI. Recently he has focused his research also on possible correlations between immunological and MRI biomarkers He has been principal investigator in several Phase II and III clinical trials.
Scientific activities are documented by more than 400 publications in high-impact journals.
Organizations
Career arc: 1995 - 2026
Number : 443
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 11
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 14
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A study to investigate long term safety and tolerability of tolebrutinib in participants with multiple sclerosis 2023-503631-18-01 — sclerosis, multiple sclerosis, safety, nervous system, nervous system diseases, primary progressive multiple sclerosis, secondary progressive multiple sclerosis | Phase 3 | Active not recruiting | 2024 |
| Non inferiority study of frexalimab subcutaneous administration compared to intravenous administration in adult participants with multiple sclerosis 2024-519304-28-00 — sclerosis, multiple sclerosis, safety, administration, intravenous, pharmacokinetics | Phase 3 | Recruiting | 2026 |
| Non inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis NCT07325292 — injections, sclerosis, multiple sclerosis, safety, pharmaceutical preparations, administration, intravenous, solutions, therapeutics, pharmacokinetics, male | Phase 3 | Recruiting | 2026 |
| Observational Longitudinal Study on the Outbreak and Management of Stroke Related Spasticity NCT05379413 — injections, muscle spasticity, longitudinal studies, muscles, stroke, rehabilitation, botulinum toxins, type a, botulinum toxins, therapeutics, neurotoxins | N/A | Not yet recruiting | 2022 |
LeadR Networks
Main global connection map